Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of riliprubart versus IVIg in adults with chronic inflammatory demyelinating polyradiculoneuropathy
MOH_2024-09-02_013602Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Aug 2024
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) (4 arms), sponsored by Sanofi. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
riliprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on MOH_2024-09-02_013602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-02_013602.